The formation of tau pore-like structures is prevalent and cell specific: Possible implications for the disease phenotypes

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Lasagna Reeves, Cristian A ^a,b,d   Sengupta, Urmi ^a,b   Castillo Carranza, Diana ^a,b   Gerson, Julia E ^a,b   Guerrero Munoz, Marcos ^a,b   Troncoso, Juan C ^c   Jackson, George R ^a,b   Kayed, Rakez ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Annular protofibrils; Oligomers; Tau; Tauopathies

Indexed keywords

MYELIN BASIC PROTEIN; TAU PROTEIN;

ANIMAL; BRAIN; CELL STRUCTURE; CHEMISTRY; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOPRECIPITATION; METABOLISM; MOUSE; MUTATION; NEUROBLASTOMA; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROGRESSIVE SUPRANUCLEAR PALSY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BRAIN; CELL LINE, TUMOR; CELLULAR STRUCTURES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOPRECIPITATION; LEWY BODY DISEASE; MICE; MICE, TRANSGENIC; MUTATION; MYELIN BASIC PROTEIN; NEUROBLASTOMA; PHOSPHORYLATION; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 84909630741     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-56     Document Type: Article

References (72)

1. Binder LI, Frankfurter A, Rebhun LI: The distribution of tau in the mammalian central nervous system. J Cell Biol 1985, 101(4):1371-1378. 10.1083/jcb.101.4.1371
2. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW: Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 1992, 3(10):1141-1154. 10.1091/mbc.3.10.1141
3. Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24: 1121-1159. doi:10.1146/annurev.neuro.24.1.1121 10.1146/annurev.neuro.24.1.1121
4. Alonso AC, Li B, Grundke-Iqbal I, Iqbal K: Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2008, 5(4):375-384. 10.2174/156720508785132307
5. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I: Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009, 118(1):53-69. doi:10.1007/s00401-009-0486-3 10.1007/s00401-009-0486-3
6. Ballatore C, Lee VM, Trojanowski JQ: Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007, 8(9):663-672. doi:10.1038/nrn2194
7. Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP: Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol Aging 2007, 28(1):1-7. doi:10.1016/j.neurobiolaging.2005.11.001 10.1016/j.neurobiolaging.2005.11.001
8. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82(4):239-259. 10.1007/BF00308809
9. Delacourte A, Buee L: Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurol 2000, 13(4):371-376. 10.1097/00019052-200008000-00002
10. Braak H, AlafuzoffI, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112(4):389-404. doi:10.1007/s00401-006-0127-z 10.1007/s00401-006-0127-z
11. Brunden KR, Trojanowski JQ, Lee VM: Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis 2008, 14(4):393-399.
12. Marx J: Alzheimer's disease. A new take on tau. Science 2007, 316(5830):1416-1417. doi:10.1126/science.316.5830.1416 10.1126/science.316.5830.1416
13. Andorfer C, Acker CM, Kress Y, Hof PR, DuffK, Davies P: Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005, 25(22):5446-5454. doi:10.1523/JNEUROSCI.4637-04.2005 10.1523/JNEUROSCI.4637-04.2005
14. Polydoro M, Acker CM, DuffK, Castillo PE, Davies P: Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009, 29(34):10741-10749. doi:10.1523/JNEUROSCI.1065-09.2009 10.1523/JNEUROSCI.1065-09.2009
15. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53(3):337-351. doi:10.1016/j.neuron.2007.01.010 10.1016/j.neuron.2007.01.010
16. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C: Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007, 27(14):3650-3662. doi:10.1523/JNEUROSCI.0587-07.2007 10.1523/JNEUROSCI.0587-07.2007
17. Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT: Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006, 168(5):1598-1607. doi:10.2353/ajpath.2006.050840 10.2353/ajpath.2006.050840
18. Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8(2):101-112. doi:10.1038/nrm2101 10.1038/nrm2101
19. Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, Chiti F, Dobson CM, Stefani M: Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci 2006, 26(31):8160-8167. doi:10.1523/JNEUROSCI.4809-05.2006 10.1523/JNEUROSCI.4809-05.2006
20. Ross CA, Poirier MA: Opinion: what is the role of protein aggregation in neurodegeneration Nat Rev Mol Cell Biol 2005, 6(11):891-898. doi:10.1038/nrm1742 10.1038/nrm1742
21. Caughey B, Lansbury PT: Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003, 26: 267-298. doi:10.1146/annurev.neuro.26.010302.081142 010302.081142 10.1146/annurev.neuro.26.010302.081142
22. Glabe CG: Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006, 27(4):570-575. doi:10.1016/j.neurobiolaging.2005.04.017 10.1016/j.neurobiolaging.2005.04.017
23. Miller Y, Ma B, Nussinov R: Synergistic interactions between repeats in tau protein and Abeta amyloids may be responsible for accelerated aggregation via polymorphic states. Biochemistry 2011, 50(23):5172-5181. doi:10.1021/bi200400u 10.1021/bi200400u
24. Hafner JH, Cheung CL, Woolley AT, Lieber CM: Structural and functional imaging with carbon nanotube AFM probes. Prog Biophys Mol Biol 2001, 77(1):73-110. 10.1016/S0079-6107(01)00011-6
25. Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr: Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002, 41(32):10209-10217. 10.1021/bi020139h
26. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr: Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418(6895):291.
27. Pountney DL, Lowe R, Quilty M, Vickers JC, Voelcker NH, Gai WP: Annular alpha-synuclein species from purified multiple system atrophy inclusions. J Neurochem 2004, 90(2):502-512. 10.1111/j.1471-4159.2004.02533.x
28. Lasagna-Reeves CA, Glabe CG, Kayed R: Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem 2011, 286(25):22122-22130. doi:10.1074/jbc. M111.236257 10.1074/jbc. M111.236257
29. Lasagna-Reeves CA, Kayed R: Astrocytes contain amyloid-beta annular protofibrils in Alzheimer's disease brains. FEBS Lett 2011, 585(19):3052-3057. doi:10.1016/j.febslet.2011.08.027 10.1016/j.febslet.2011.08.027
30. Lashuel HA, Lansbury PT Jr: Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins Q Rev Biophys 2006, 39(2):167-201. doi:10.1017/S0033583506004422 10.1017/S0033583506004422
31. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C: Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 2009, 284(7):4230-4237. doi:10.1074/jbc. M808591200 10.1074/jbc. M808591200
32. Montoya M, Gouaux E: Beta-barrel membrane protein folding and structure viewed through the lens of alpha-hemolysin. Biochim Biophys Acta 2003, 1609(1):19-27. 10.1016/S0005-2736(02)00663-6
33. Parker MW, Feil SC: Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol 2005, 88(1):91-142. 10.1016/j.pbiomolbio.2004.01.009
34. Glabe CG, Kayed R: Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 2006, 66(2 Suppl 1):S74-S78. doi:10.1212/01.wnl.0000192103.24796.42
35. Kokubo H, Kayed R, Glabe CG, Staufenbiel M, Saido TC, Iwata N, Yamaguchi H: Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. Int J Alzheimers Dis 2009., 2009: doi:10.4061/2009/689285
36. Margittai M, Langen R: Template-assisted filament growth by parallel stacking of tau. Proc Natl Acad Sci USA 2004, 101(28):10278-10283. doi:10.1073/pnas.0401911101 0401911101 10.1073/pnas.0401911101
37. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R: Preparation and characterization of neurotoxic tau oligomers. Biochemistry 2010, 49(47):10039-10041. doi:10.1021/bi1016233 10.1021/bi1016233
38. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R: Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 2011, 6: 39. doi:10.1186/1750-1326-6-39 10.1186/1750-1326-6-39
39. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, DuffK, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000, 25(4):402-405. doi:10.1038/78078 10.1038/78078
40. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R: Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J 2012, 26(5):1946-1959. doi:10.1096/fj.11-199851 10.1096/fj.11-199851
41. Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, Lees A, Yamamoto T, Kosaka K: Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol 2003, 105(3):265-270. doi:10.1007/s00401-002-0644-3
42. Yoshida M: Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 2006, 26(5):457-470. 10.1111/j.1440-1789.2006.00743.x
43. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002, 103(1):26-35. 10.1007/s004010100423
44. Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C, Hall JE: Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 2006, 128(6):637-647. doi:10.1085/jgp.200609533 10.1085/jgp.200609533
45. Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R: Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 2005, 102(30):10427-10432. doi:10.1073/pnas.0502066102 10.1073/pnas.0502066102
46. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG: Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004, 279(45):46363-46366. doi:10.1074/jbc. C400260200 C400260200 10.1074/jbc. C400260200
47. Engel MF, Khemtemourian L, Kleijer CC, Meeldijk HJ, Jacobs J, Verkleij AJ, de KruijffB, Killian JA, Hoppener JW: Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc Natl Acad Sci USA 2008, 105(16):6033-6038. doi:10.1073/pnas.0708354105 10.1073/pnas.0708354105
48. Zhu M, Li J, Fink AL: The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem 2003, 278(41):40186-40197. 10.1074/jbc. M305326200
49. Chen F-Y, Lee M-T, Huang HW: Evidence for membrane thinning effect as the mechanism for peptide-induced pore formation. Biophys J 2003, 84(6):3751-3758. 10.1016/S0006-3495(03)75103-0
50. Modler AJ, Gast K, Lutsch G, Damaschun G: Assembly of amyloid protofibrils via critical oligomers-a novel pathway of amyloid formation. J Mol Biol 2003, 325(1):135-148. 10.1016/S0022-2836(02)01175-0
51. Porat Y, Kolusheva S, Jelinek R, Gazit E: The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 2003, 42(37):10971-10977. 10.1021/bi034889i
52. Pooler AM, Hanger DP: Functional implications of the association of tau with the plasma membrane. Biochem Soc Trans 2010, 38(4):1012-1015. doi:10.1042/BST0381012 10.1042/BST0381012
53. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP: Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 2012, 33(2):431. e427-438. doi:10.1016/j.neurobiolaging.2011.01.005
54. Maas T, Eidenmuller J, Brandt R: Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 2000, 275(21):15733-15740. doi:10.1074/jbc. M000389200 10.1074/jbc. M000389200
55. Bhaskar K, Yen SH, Lee G: Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem 2005, 280(42):35119-35125. doi:10.1074/jbc. M505895200 10.1074/jbc. M505895200
56. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142(3):387-397. doi:10.1016/j.cell.2010.06.036 10.1016/j.cell.2010.06.036
57. Flach K, Hilbrich I, Schiffmann A, Gartner U, Kruger M, Leonhardt M, Waschipky H, Wick L, Arendt T, Holzer M: Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem 2012, 287(52):43223-43233. doi:10.1074/jbc. M112.396176 10.1074/jbc. M112.396176
58. Pountney DL, Lowe R, Quilty M, Vickers JC, Voelcker NH, Gai WP: Annular alpha-synuclein species from purified multiple system atrophy inclusions. J Neurochem 2004, 90(2):502-512. doi:10.1111/j.1471-4159.2004.02533.x 10.1111/j.1471-4159.2004.02533.x
59. Arispe N, Pollard HB, Rojas E: Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc Natl Acad Sci USA 1993, 90(22):10573-10577. 10.1073/pnas.90.22.10573
60. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC: The channel hypothesis of Alzheimer's disease: current status. Peptides 2002, 23(7):1311-1315. 10.1016/S0196-9781(02)00067-0
61. Di Scala C, Troadec J-D, Lelièvre C, Garmy N, Fantini J, Chahinian H: Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β -amyloid peptide. J Neurochem 2013. n/a-n/a. doi:10.1111/jnc.12390
62. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, Nussinov R, Lal R: Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's disease and down syndrome. Proc Natl Acad Sci USA 2010, 107(14):6538-6543. doi:10.1073/pnas.0914251107 10.1073/pnas.0914251107
63. Bordji K, Becerril-Ortega J, Buisson A: Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer's disease. Rev Neurosci 2011., 22: doi:10.1515/rns.2011.029
64. Yamaguchi H, Maat-Schieman ML, van Duinen SG, Prins FA, Neeskens P, Natte R, Roos RA: Amyloid beta protein (Abeta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects. J Neuropathol Exp Neurol 2000, 59(8):723-732.
65. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ: Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010, 285(12):9262-9272. doi:10.1074/jbc. M109.081125 10.1074/jbc. M109.081125
66. Nishimura M, Tomimoto H, Suenaga T, Namba Y, Ikeda K, Akiguchi I, Kimura J: Immunocytochemical characterization of glial fibrillary tangles in Alzheimer's disease brain. Am J Pathol 1995, 146(5):1052-1058.
67. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M: Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002, 22(21):9340-9351.
68. Ren Y, Lin WL, Sanchez L, Ceballos C, Polydoro M, Spires-Jones TL, Hyman BT, Dickson DW, Sahara N: Endogenous Tau Aggregates in Oligodendrocytes of rTg4510 Mice Induced by Human P301L Tau. J Alzheimers Dis 2013. doi:10.3233/JAD-130986
69. Klein C, Kramer EM, Cardine AM, Schraven B, Brandt R, Trotter J: Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau. J Neurosci 2002, 22(3):698-707.
70. Hoos MD, Ahmed M, Smith SO, Van Nostrand WE: Myelin basic protein binds to and inhibits the fibrillar assembly of Abeta42 in vitro. Biochemistry 2009, 48(22):4720-4727. doi:10.1021/bi900037s 10.1021/bi900037s
71. Liao MC, Hoos MD, Aucoin D, Ahmed M, Davis J, Smith SO, Van Nostrand WE: N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly. J Biol Chem 2010, 285(46):35590-35598. doi:10.1074/jbc. M110.169599 10.1074/jbc. M110.169599
72. Liao MC, Ahmed M, Smith SO, Van Nostrand WE: Degradation of amyloid beta protein by purified myelin basic protein. J Biol Chem 2009, 284(42):28917-28925. doi:10.1074/jbc. M109.050856 10.1074/jbc. M109.050856